Calithera Biosciences Raises $10M Via Equity Issued At 10% Discount
Calithera Biosciences Inc (NASDAQ:CALA) priced its previously announced underwritten public offering of 18.5 million shares at $0.54 per share for gross proceeds…
Preview: Calithera Biosciences’s Earnings
Calithera Biosciences (NASDAQ:CALA) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement.
Analysts estimate that Calithera Biosciences will report an earnings per share (EPS) of $-0.24.
12 Health Care Stocks Moving In Wednesday’s Pre-Market Session
Gainers
Adagio Therapeutics (NASDAQ:ADGI) shares increased by 52.2% to $5.86 during Wednesday's pre-market session. The company's market cap stands at $651.9 million.
50 Biggest Movers From Yesterday
Gainers
Hycroft Mining Holding Corporation (NASDAQ: HYMC) shares gained 81.3% to close at $2.32 on Monday. Last week, AMC Entertainment Holdings purchased a major stake in Hycroft Mining Holding.
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Oncternal Therapeutics (NASDAQ:ONCT) shares moved upwards by 7.0% to $2.0 during Monday's after-market session. The company's market cap stands at $98.8 million.
Ladenburg Thalmann Initiates Coverage On Calithera Biosciences with Buy Rating, Announces Price Target of $4
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Calithera Biosciences (NASDAQ:CALA) with a Buy rating and announces Price Target of $4.
